Nektar Therapeutics
NKTR
Rank in Stocks
#8338
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global... Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Share Price
$37.83
Last synced: 2026-11-09
Market Cap
$1.09B
Change (1 day)
1.52%
Change (1 year)
-33.27%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nektar Therapeutics (NKTR)
Category
Healthcare
EPS for Nektar Therapeutics (NKTR)
EPS as of June 2026 TTM: $-6.70
According to Nektar Therapeutics's latest financial reports, its current EPS (TTM) is $-6.70. At the end of 2025 the company had an EPS of $-9.73, a decrease compared to its 2024 EPS of $-8.68.
EPS history for Nektar Therapeutics from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-6.70 | -31.14% |
| 2025 | $-9.73 | 12.10% |
| 2024 | $-8.68 | -60.17% |
| 2023 | $-21.79 | -26.16% |
| 2022 | $-29.51 | -31.21% |
| 2021 | $-42.90 | 14.92% |
| 2020 | $-37.33 | -1.24% |
| 2019 | $-37.80 | -166.67% |
| 2018 | $56.70 | -709.68% |
| 2017 | $-9.30 | -43.64% |
| 2016 | $-16.50 | 80.33% |
| 2015 | $-9.15 | 45.24% |
| 2014 | $-6.30 | -70.00% |
| 2013 | $-21.00 | -6.67% |
| 2012 | $-22.50 | 26.05% |
| 2011 | $-17.85 | 197.50% |
| 2010 | $-6.00 | -63.96% |
| 2009 | $-16.65 | 200.00% |
| 2008 | $-5.55 | 2.78% |
| 2007 | $-5.40 | -79.07% |
| 2006 | $-25.80 | -20.00% |
| 2005 | $-32.25 | 65.38% |
| 2004 | $-19.50 | 54.76% |
| 2003 | $-12.60 | -56.70% |
| 2002 | $-29.10 | -58.81% |
| 2001 | $-70.65 | 103.02% |
| 2000 | $-34.80 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -333.73% |
US
|
|
| $-7.07 | 5.52% |
US
|
|
| $-5.29 | -21.04% |
AU
|
|
| $12.88 | -292.24% |
BE
|
|
| $21.56 | -421.79% |
NL
|
Questions about Nektar Therapeutics's earnings per share (EPS)
What is Nektar Therapeutics's earnings per share (EPS)?
Nektar Therapeutics's earnings per share (EPS) over the last twelve months is $-6.70, as of Jun 2026.
What was Nektar Therapeutics's earnings per share (EPS) in 2025?
In 2025, Nektar Therapeutics's earnings per share (EPS) was $-9.73, compared with $-8.68 in 2024.
How has Nektar Therapeutics's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Nektar Therapeutics's earnings per share (EPS) was highest in 2024 ($-8.68) and lowest in 2021 ($-42.90).
How does Nektar Therapeutics's earnings per share (EPS) compare with similar companies?
Nektar Therapeutics's earnings per share (EPS) ($-6.70) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.